Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.
Follow AGEN
Agenus Inc. (AGEN) EV/Sales
As of 16 October 2026, Agenus Inc. (AGEN) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from 0.2× (August 2024) to 55.4× (June 2015); the current reading is higher than 32% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | 178.69% |
| FY2024 | 0.5× | (65.08%) |
| FY2023 | 1.4× | (71.06%) |
| FY2022 | 4.9× | 239.10% |
| FY2021 | 1.5× | (72.01%) |
| FY2020 | 5.2× | 58.68% |
| FY2019 | 3.3× | (45.00%) |
| FY2018 | 6.0× | (42.60%) |
| FY2017 | 10.4× | (42.85%) |
| FY2016 | 18.2× | 54.64% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.2× | 3.55% |
| Mar 2026 | 1.2× | (15.42%) |
| Dec 2025 | 1.4× | (3.34%) |
| Sep 2025 | 1.4× | (4.37%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | −0.5× |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| AGEN Agenus Inc. | 2.1× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 6.1× |
| SRZN Surrozen, Inc. compare | 14.9× |
| OCGN Ocugen, Inc. compare | 36.2× |
| CYPH Cypherpunk Technologies Inc. compare | 311× |
| BNTC Benitec Biopharma Limited compare | 2,637× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)